Navigation Links
Oncothyreon announces issuance of patent for PX-867
Date:3/20/2008

have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.

Forward Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements related to filing an IND for PX-866, future clinical development plans for PX-866, and plans to seek a collaboration partner for PX-867. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, the safety and efficacy of PX-866 and PX-867, and the likelihood of achieving a collaboration agreement for PX-867. There can be no guarantee that the results of preclinical studies will be predictive of either safety or efficacy in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon to present at upcoming investment conferences
2. Oncothyreon reports full year and fourth quarter 2007 financial results
3. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
4. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
5. Oncothyreon launches new corporate website
6. Oncothyreon to present at BIO CEO & Investor Conference
7. Oncothyreon highlights corporate and clinical objectives for 2008
8. Biomira announces plan to change name to Oncothyreon
9. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
10. Society for Biomolecular Sciences Announces 2008 Conference Speaker Line-up
11. BioMS Medical Announces 2007 Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's web-based ... the product choices to a manageable shortlist of bench and floor scales and ... that fit best with the customer’s industry and application. , Side-by-side product ...
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
(Date:8/26/2015)... 2015  Platform therapeutic company Symic Biomedical, Inc. ... $1.5M Phase II SBIR grant from the National ... therapeutic agent to reduce arteriovenous fistula (AVF) failures, ... renal disease (ESRD) patients undergoing hemodialysis. The two-year ... and Digestive and Kidney Diseases (NIDDK), will allow ...
(Date:8/26/2015)... 2015 After litigating and negotiating patent ... to P2i United States patent RE43,651 ... the United States without any admission ... either party. As a result of the parties, settlement, the ... California dismissed the case without prejudice. ...
Breaking Biology Technology:METTLER TOLEDO Updates Online Scale Selection Tool 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3P2i Settles United States Litigation 2
... 2011 Sequenom, Inc. (NASDAQ: SQNM ), a ... the Company,s participation at the 23rd Annual Piper Jaffray Healthcare ... 29-30, 2011. Ronald M. Lindsay, Ph.D., Director ... CFO, will present on Tuesday, November 29, 2011 beginning at ...
... hurdles to be cleared before human embryonic stem cells can ... cells can functionally integrate into target organs or tissues. ... the National Academy of Sciences, a team of Wisconsin ... slate human embryonic stem cells and implanted into the brains ...
... Carbon nanotubes, tiny cylinders composed of one-atom-thick carbon lattices, have ... science. Now a group of researchers from the University of ... unique properties, the low refractive index of low-density aligned nanotubes, ... nothing more than a flat, black sheet. The ...
Cached Biology Technology:Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference 2Implanted neurons, grown in the lab, take charge of brain circuitry 2Implanted neurons, grown in the lab, take charge of brain circuitry 3
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
(Date:7/31/2015)... , 31 de julio de 2015 ... (ICG-10,  www.icg-10.org ) del 22 al 25 de octubre ... La conferencia celebra su décimo aniversario este ... convertido en una de las reuniones anuales más influyentes ... es una de las conferencias científicas más dinámicas, entusiastas ...
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... has filed provisional patent 62/198989 for ELECTRONIC ... highlights a method to advance crypto-currencies such as Bitcoin ... a common, uniform way to manage all payments.  ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... rulers, capable of measuring nanometer-scale spatial changes in ... the U.S. Department of Energy (DOE),s Lawrence Berkeley ... at the University of Stuttgart, Germany. These 3D ... on such critical dynamic events in biology as ...
... is the functional study of the entire set of sugars ... sound like a distant cousin of more familiar names such ... several species have been extensively investigated in the last years, ... in Science magazine by an international collaboration headed ...
... the University of Colorado Boulder a six-year, $5.9 ... ecological changes in Colorado,s high mountains, both natural ... to CU-Boulder,s Institute of Arctic and Alpine Research, ... including undergraduates, to continue key environmental studies at ...
Cached Biology News:Taking the 3-D measure of macromolecules: 2Taking the 3-D measure of macromolecules: 3The sweet growth of plant cells 2NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 2NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 3NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 4
... FilterMate is a compact, versatile system that ... 96- or 24-well microplates into a solid ... liquid scintillation and gamma counter. The FilterMate ... for applications such as cell proliferation, receptor ...
... a single fragment based screening project: , ... 96 shape-diverse mixtures of 4 (5 uL each) ... structure refinement , Individual compounds are dissolved ... ca. 50 mM. Supplied in 5 96-well trays. ...
... (Catalog number SCR004) is a specific and ... ES cell differentiation by the determination of ... are the monoclonal antibodies TRA-2-49 (Catalog Number ... permit the detection of Liver / Bone ...
Rabbit polyclonal to Shigella Immunogen: Mixture of S. boydii, S. flexneri & S. dysenteriae....
Biology Products: